CoChat

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice

Open access
Ideta, Takayasu, Shirakami, Yohei, Miyazaki, Tsuneyuki, Kochi, Takahiro, Sakai, Hiroyasu, Moriwaki, Hisataka, Shimizu, Masahito · 2015 · International Journal of Molecular Sciences
Cited by 58

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Non-alcoholic fatty liver disease (NAFLD), which is strongly associated with metabolic syndrome, is increasingly a major cause of hepatic disorder. Dipeptidyl peptidase (DPP)-4 inhibitors, anti-diabetic agents, are expected to be effective for the treatment of NAFLD. In the present study, we established a novel NAFLD model mouse using monosodium glutamate (MSG) and a high-fat diet (HFD) and investigated the effects of a DPP-4 inhibitor, teneligliptin, on the progression of NAFLD. Male MSG/HFD-treated mice were divided into two groups, one of which received teneligliptin in drinking water. Administration of MSG and HFD caused mice to develop severe fatty changes in the liver, but teneligliptin treatment improved hepatic steatosis and inflammation, as evaluated by the NAFLD activity score. Serum alanine aminotransferase and intrahepatic triglyceride levels were significantly decreased in teneligliptin-treated mice (p < 0.05). Hepatic mRNA levels of the genes involved in de novo lipogenesis were significantly downregulated by teneligliptin (p < 0.05). Moreover, teneligliptin increased hepatic expression levels of phosphorylated AMP-activated protein kinase (AMPK) protein. These findings suggest that teneligliptin attenuates lipogenesis in the liver by activating AMPK and downregulating the expression of genes involved in lipogenesis. DPP-4 inhibitors may be effective for the treatment of NAFLD and may be able to prevent its progression to non-alcoholic steatohepatitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms161226156

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 42

  1. Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N. Engl. J. Med., 348, 1625, 10.1056/NEJMoa021423 · DOI · Paper page
  2. Chalasani, 2012, The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the american gastroenterological association, Hepatology, 55, 2005, 10.1002/hep.25762 · DOI · Paper page
  3. Sass, 2005, Nonalcoholic fatty liver disease: A clinical review, Dig. Dis. Sci., 50, 171, 10.1007/s10620-005-1267-z · DOI · Paper page
  4. Bacon, 1994, Nonalcoholic steatohepatitis: An expanded clinical entity, Gastroenterology, 107, 1103, 10.1016/0016-5085(94)90235-6 · DOI · Paper page
  5. Kim, 2008, Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome, Clevel. Clin. J. Med., 75, 721, 10.3949/ccjm.75.10.721 · DOI · Paper page
  6. Vanni, 2010, From the metabolic syndrome to NAFLD or vice versa?, Dig. Liver Dis., 42, 320, 10.1016/j.dld.2010.01.016 · DOI · Paper page
  7. Ascha, 2010, The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis, Hepatology, 51, 1972, 10.1002/hep.23527 · DOI · Paper page
  8. Marchesini, 1999, Association of nonalcoholic fatty liver disease with insulin resistance, Am. J. Med., 107, 450, 10.1016/S0002-9343(99)00271-5 · DOI · Paper page
  9. Sanyal, 2002, Aga technical review on nonalcoholic fatty liver disease, Gastroenterology, 123, 1705, 10.1053/gast.2002.36572 · DOI · Paper page
  10. Shimizu, 2011, Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice, BMC Cancer, 11, 281, 10.1186/1471-2407-11-281 · DOI
  11. Shimizu, 2011, Preventive effects of (−)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice, Cancer Prev. Res., 4, 396, 10.1158/1940-6207.CAPR-10-0331 · DOI
  12. Ohno, 2015, Metformin suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-+Leprdb/+Leprdb mice, PLoS ONE, 10, e0124081, 10.1371/journal.pone.0124081 · DOI
  13. Lonardo, 2015, Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome, Dig. Liver Dis., 47, 181, 10.1016/j.dld.2014.09.020 · DOI · Paper page
  14. Zhang, 2015, Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified bayesian network in a chinese population, BMJ Open, 5, e008204, 10.1136/bmjopen-2015-008204 · DOI
  15. Aschner, 2006, Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes, Diabetes Care, 29, 2632, 10.2337/dc06-0703 · DOI · Paper page
  16. Schweizer, 2007, Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes, Diabetes Res. Clin. Pract., 76, 132, 10.1016/j.diabres.2006.12.009 · DOI · Paper page
  17. Klein, 2014, Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis, Med. Mol. Morphol., 47, 137, 10.1007/s00795-013-0053-9 · DOI
  18. Schuppan, 2010, The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis, Liver Int., 30, 795, 10.1111/j.1478-3231.2010.02264.x · DOI
  19. Yilmaz, 2009, Dipeptidyl peptidase IV inhibitors: Therapeutic potential in nonalcoholic fatty liver disease, Med. Sci. Res., 15, HY1-5
  20. Collison, 2012, Interactive effects of neonatal exposure to monosodium glutamate and aspartame on glucose homeostasis, Nutr. Metabol., 9, 58, 10.1186/1743-7075-9-58 · DOI
  21. Nagata, 2006, Type 2 diabetes mellitus in obese mouse model induced by monosodium glutamate, Exp. Anim. Jpn. Assoc. Lab. Anim. Sci., 55, 109
  22. Jasso, 2011, Monosodium glutamate neonatal intoxication associated with obesity in adult stage is characterized by chronic inflammation and increased mRNA expression of peroxisome proliferator-activated receptors in mice, Basic Clin. Pharmacol. Toxicol., 108, 406, 10.1111/j.1742-7843.2011.00671.x · DOI
  23. Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
  24. Li, 2011, AMPK phosphorylates and inhibits Srebp activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice, Cell Metabol., 13, 376, 10.1016/j.cmet.2011.03.009 · DOI · Paper page
  25. Serviddio, 2013, Free radical biology for medicine: Learning from nonalcoholic fatty liver disease, Free Radic. Biol. Med., 65, 952, 10.1016/j.freeradbiomed.2013.08.174 · DOI · Paper page
  26. Blaslov, 2014, Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease, World J. Gastroenterol., 20, 7356, 10.3748/wjg.v20.i23.7356 · DOI · Paper page
  27. Shimizu, 2011, Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J- +leprdb/+leprdb mice, Cancer Prev. Res., 4, 128, 10.1158/1940-6207.CAPR-10-0163 · DOI
  28. Musso, 2009, Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD), Progress Lipid Res., 48, 1, 10.1016/j.plipres.2008.08.001 · DOI · Paper page
  29. Higuchi, 2008, Liver X receptor in cooperation with Srebp-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease, Hepatol. Res., 38, 1122, 10.1111/j.1872-034X.2008.00382.x · DOI · Paper page
  30. Kern, 2012, Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity, PLoS ONE, 7, e38744, 10.1371/journal.pone.0038744 · DOI
  31. Singh, 2015, Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis, Hepatology, 62, 1417, 10.1002/hep.27999 · DOI · Paper page
  32. Shirakami, Y., Shimizu, M., Kubota, M., Ohno, T., Kochi, T., Nakamura, N., Sumi, T., Tanaka, T., Moriwaki, H., and Seishima, M. (2015). Pentoxifylline prevents nonalcoholic steatohepatitis-related liver pre-neoplasms by inhibiting hepatic inflammation and lipogenesis. Eur. J. Cancer Prev. · doi:10.1097/cej.0000000000000172
  33. Hardie, 2012, Ampk: A nutrient and energy sensor that maintains energy homeostasis, Nat. Rev. Mol. Cell Biol., 13, 251, 10.1038/nrm3311 · DOI · Paper page
  34. Viollet, 2007, Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders, Diabetes Metab., 33, 395, 10.1016/j.diabet.2007.10.004 · DOI · Paper page
  35. Zvibel, 2011, Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase, J. Hepatol., 54, 1214, 10.1016/j.jhep.2010.09.032 · DOI · Paper page
  36. Samson, 2013, Potential of incretin-based therapies for non-alcoholic fatty liver disease, J. Diabetes Complicat., 27, 401, 10.1016/j.jdiacomp.2012.12.005 · DOI
  37. Boschmann, 2009, Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients, J. Clin. Endocrinol. Metab., 94, 846, 10.1210/jc.2008-1400 · DOI · Paper page
  38. Shimizu, 2009, Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice, Clin. Cancer Res., 15, 3068, 10.1158/1078-0432.CCR-08-2093 · doi:10.1158/1078-0432.ccr-08-2093
  39. Primer Blast, Available online: http://www.ncbi.nlm.nih.gov/tools/primer-blast/.
  40. Folch, 1957, A simple method for the isolation and purification of total lipides from animal tissues, J. Biol. Chem., 226, 497, 10.1016/S0021-9258(18)64849-5 · DOI · Paper page
  41. Iwasa, 2010, Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice, Cancer Sci., 101, 460, 10.1111/j.1349-7006.2009.01402.x · DOI · Paper page
  42. Miyazaki, 2012, Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism, Mol. Med. Rep., 5, 729

Cited by

See all 58

Metadata

Authors
Ideta, T., Shirakami, Y., Miyazaki, T., Kochi, T., Sakai, H., Moriwaki, H., & Shimizu, M.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2015-12-08
Volume
16
Issue
12
Pages
29207-29218
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2190193027
Cited by
58
References
7
FWCI
4.59
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. https://app.cochat.ai/papers/10.3390/ijms161226156
The paper
Ideta, T., Shirakami, Y., Miyazaki, T., Kochi, T., Sakai, H., Moriwaki, H., & Shimizu, M. (2015). The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms161226156

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.